Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Dose-Adjusted EPOCH ± Rituximab + Ponatinib for Adults With Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

NCT07224100 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT07224100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07224100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Dose-Adjusted EPOCH ± Rituximab + Ponatinib for Adults With Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Recruiting
Start date
March 30, 2026
Completion date
July 31, 2028
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); bcr-abl1, b lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2); bcr-abl1, lymphoblastic lymphoma